Frankincense oil research combats melanoma

June 2006
DVM: The Newsmagazine of Veterinary Medicine;Jun2006, Vol. 37 Issue 6, p1E
The article reports on a study by John Robertson, director of the University of Virginia-Maryland Center for Comparative Oncology, on the use of frankincense oil as a possible treatment for malignant melanoma in horses, as he has presented at the American Cancer Society's meeting in Roanoke. Frankincense oil is a fragrant botanical oil distillate from fermented plants. It contains boswellic acid, which has anti-neoplastic properties. The oil also has anti-inflammatory effects.


Related Articles

  • Novel Protein Targeted Therapy of Metastatic Melanoma. Frankel, Arthur E.; Han-Mo Koo; Leppla, Stephen H.; Duesbery, Nicholas S.; Vande Woude, George F. // Current Pharmaceutical Design;Oct2003, Vol. 9 Issue 25, p2060 

    Metastatic melanoma patients have a dismal prognosis with poor responsiveness to chemotherapy, radiation therapy and current immunotherapy regimens and a median survival of less than six months. Novel therapies directed at melanoma-selective molecular targets are urgently needed. Based on the...

  • Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report. Salmaggi, A.; Silvani, A.; Eoli, M.; Lamperti, E.; Boiardi, A. // Neurological Sciences;Dec2002, Vol. 23 Issue 5, p257 

    Focuses on the administration of temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma. Neoplastic dissemination involving leptomeninges; Effect of temozolomide on brain metastases from melanoma.

  • Prolonged low-dose interferon alpha2a therapy showed no benefit in melanoma.  // Hem/Onc Today;2/10/2010, Vol. 11 Issue 3, p23 

    The article discusses research on the effect of prolonging low-dose interferon alpha2a therapy for patients with intermediate or high-risk lymph-node negative melanoma, that references a study by A. Hauschild and colleagues published in a 2009 issue of the "Journal of Clinical Oncology."

  • FRANKINCENSE: A SCENT FROM THE BIBLE. Rose, Jeanne; Karydas, Rita C. // Aromatic News;Fall2003, p3 

    Presents a medical research on olibanum, a pure essential oil of frankincense, which is a gum resin obtained from various Arabian and African trees and used in perfumes and as incense. Physicochemical properties of olibanol, which is a chemical component of frankincense; Historical data on the...

  • In The Cradle Of Scent.  // Conde Nast Traveler;Jan2013, Vol. 48 Issue 1, p28 

    The article traces the origin of the perfume industry in the Sultanate of Oman. Dhofar is considered one of the world's best frankincense as well as the Arab world's finest bakhoor, incense hand-blended from resins, powdered flowers, perfumed oils, ground seashells, and other aromatics. The...

  • Dose-dependent severe cutaneous reactions to imatinib. Ugurel, S.; Hildenbrand, R.; Dippel, E.; Hochhaus, A.; Schadendorf, D. // British Journal of Cancer;4/22/2003, Vol. 88 Issue 8, p1157 

    The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities, We here report on two out of four melanoma patients treated with high-dose imatinib presenting; with severe and strongly dose dependent skin eruptions, suggesting a...

  • Velimogene aliplasmid inferior to chemotherapy in advanced melanoma. Todak, Alexandra // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p22 

    The article cites the study "Plasmid DNA-based immunotherapy for metastatic melanoma: A phase 3 trial of velimogene aliplasmid," led by Sanjiv S. Agarwala, on the inferior response of advanced melanoma patients receiving velimogene aliplasmid compared to those receiving dacarbazine or temozolomide.

  • Velimogene aliplasmid, T-VEC studies put intralesional immunotherapy into perspective. Todak, Alexandra // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p22 

    The author discusses studies and clinical trials which confirm that intralesional immunotherapy can result in local tumor destruction in recurrent or metastatic melanoma and the characteristics of an ideal intralesional agent.

  • T-VEC extended OS in metastatic melanoma. Todak, Alexandra // Hem/Onc Today;1/25/2014, Vol. 15 Issue 2, p22 

    The article discusses the study "Interim OS subset analyses in OPTiM, a randomized phase 3 trial of intralesional talimogene laherparepvec vs. subcutaneous granulocyte-macrophage colony-stimulating factor in stage IIIB-IV melanoma," led by Howard L. Kaufman.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics